Example: Heart Attack

Search clinical trials for: Fulvestrant

Total 280 results

NCT02657343

Active, not recruiting

An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.

Conditions: Breast Cancer
NCT04862663

Recruiting

Capivasertib + Palbociclib + Fulvestrant for HR+/HER2- Advanced Breast Cancer (CAPItello-292).

Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer
NCT04738292

Recruiting

Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)

Conditions: ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Cancer
NCT04191499

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer

Conditions: Breast Cancer
NCT04936295

Recruiting

Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation

Conditions: Breast Cancer
NCT02437318

Active, not recruiting

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

Conditions: Breast Cancer
NCT02333370

Active, not recruiting

A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Conditions: Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
NCT02675231

Active, not recruiting

A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

Conditions: Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer
NCT03056755

Active, not recruiting

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

Conditions: Breast Cancer
NCT02340221

Active, not recruiting

A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy

Conditions: Breast Cancer
NCT04556773

Recruiting

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

Conditions: Metastatic Breast Cancer
NCT04224272

Recruiting

A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer

Conditions: HER2+/HR+ Breast Cancer
NCT03079011

Active, not recruiting

PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection

Conditions: Metastatic Breast Cancer
NCT04603183

Recruiting

ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL

Conditions: Breast Cancer Metastatic
NCT02860000

Active, not recruiting

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

Conditions: Estrogen Receptor Status, HER2/Neu Negative, Invasive Breast Carcinoma, Postmenopausal, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
NCT02057133

Active, not recruiting

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Conditions: Breast Neoplasms
NCT04576455

Recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Conditions: Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
NCT04650581

Recruiting

Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

Conditions: Breast Cancer
NCT02947685

Active, not recruiting

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

Conditions: HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
NCT04588298

Recruiting

A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer

Conditions: HER2-negative Breast Cancer
NCT02422615

Active, not recruiting

Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.

Conditions: Advanced Breast Cancer
NCT02763566

Active, not recruiting

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer

Conditions: Breast Cancer
NCT01296555

Active, not recruiting

A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

Conditions: Solid Cancers, Non-Hodgkin's Lymphoma
NCT03584009

Completed

A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

Conditions: Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
NCT03280563

Recruiting

A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Conditions: Breast Neoplasms